Investor relations

Stem Cell Sciences is the leader in providing stem cells on an industrial scale for drug discovery.

“With the changes that have been instigated, Stem Cell Sciences is well positioned to take advantage of the upsurge in demand for stem cells and stem cell technologies as pharmas extend their use for drug discovery and regenerative medicine from the laboratory into clinical trials.”

Alastair Riddell, CEO

We address some of the most pressing needs facing the pharmaceutical industry and research institutes to supply stem cells in high volume, with consistency and physiological relevance. Since 1994, we have led the field in proving technologies to grow, differentiate and purify embryonic and neural stem cells. We have succeeded in productising the production of stem cells and offer a wide variety of ways – patented technologies, proprietary cells, automated processes and services – to accelerate the drug discovery cycle.

Headquartered in Cambridge, Cambridgeshire, Stem Cell Sciences is a public company quoted on AIM at the London Stock Exchange and on the Australian Securities Exchange.

Stem Cell Sciences is incorporated in the UK and its main country of operation is the UK from offices in Cambridge. We also have an operating company in Melbourne, Australia and a business development office in California (USA).

The information in this part of the website is being disclosed for the purposes of Rule 26 of the AIM Rules for Companies.

Corporate Information

Registered Offices	Investor Contacts
Stem Cell Sciences plc: Incorporated and Registered in England and Wales. Registered office: Meditrina Building 260 Babraham Research Campus Cambridge CB22 3AT Registration Number: 5455929 VAT Number: 870 4274 24	Alastair Riddell (CEO) Tel: +44 (0)1223 499160 Fax: +44 (0)1223 499178